TIPRL

Summary

TIPRL (TOR signaling pathway regulator, HGNC:30231) is a protein-coding gene on chromosome 1q24.2, encoding TIP41-like protein (O75663). May be a allosteric regulator of serine/threonine-protein phosphatase 2A (PP2A). It is a selective cancer dependency (DepMap: 40.6% of cell lines).

TIPRL is an inhibitory regulator of protein phosphatase-2A (PP2A) (see PPP2CA; MIM 176915), PP4 (see PPP4C; MIM 602035), and PP6 (see PPP6C; MIM 612725) (McConnell et al., 2007 [PubMed 17384681]).

Source: NCBI Gene 261726 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 35 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 40.6% of screened cell lines
• MANE Select transcript: NM_152902

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30231
Approved symbol	TIPRL
Name	TOR signaling pathway regulator
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC3794, dJ69E11.3, TIP41, TIPRL1
Ensembl gene	ENSG00000143155
Ensembl biotype	protein_coding
OMIM	611807
Entrez	261726

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000367830, ENST00000367833, ENST00000940324, ENST00000940325, ENST00000940326

RefSeq mRNA: 2 — MANE Select: NM_152902 NM_001031800, NM_152902

CCDS: CCDS1270, CCDS30935

Canonical transcript exons

ENST00000367833 — 7 exons

Exon	Start	End
ENSE00000958402	168183902	168184081
ENSE00000958403	168184779	168184878
ENSE00000958404	168191369	168191500
ENSE00001193861	168198919	168198981
ENSE00001193868	168196547	168196642
ENSE00001445713	168199903	168202109
ENSE00001445714	168178962	168179181

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 97.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.9554 / max 487.5155, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6473	23.0984	1813
6474	10.2962	1774
6475	2.9543	1478
201805	0.6066	339

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cauda epididymis	UBERON:0004360	97.20	gold quality
caput epididymis	UBERON:0004358	95.64	gold quality
tongue squamous epithelium	UBERON:0006919	95.50	gold quality
corpus epididymis	UBERON:0004359	95.31	gold quality
cortical plate	UBERON:0005343	95.02	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.50	gold quality
nipple	UBERON:0002030	94.43	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.25	gold quality
saphenous vein	UBERON:0007318	93.90	gold quality
mammary duct	UBERON:0001765	93.73	gold quality
entorhinal cortex	UBERON:0002728	93.65	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.60	gold quality
hair follicle	UBERON:0002073	93.39	gold quality
colonic mucosa	UBERON:0000317	93.35	gold quality
epithelium of mammary gland	UBERON:0003244	93.14	gold quality
pylorus	UBERON:0001166	92.94	gold quality
vena cava	UBERON:0004087	92.92	gold quality
adrenal tissue	UBERON:0018303	92.87	gold quality
ganglionic eminence	UBERON:0004023	92.83	gold quality
pons	UBERON:0000988	92.19	gold quality
CA1 field of hippocampus	UBERON:0003881	92.17	silver quality
parietal lobe	UBERON:0001872	92.16	gold quality
gingiva	UBERON:0001828	92.15	gold quality
gingival epithelium	UBERON:0001949	92.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.13	gold quality
calcaneal tendon	UBERON:0003701	92.13	gold quality
cardia of stomach	UBERON:0001162	92.12	gold quality
seminal vesicle	UBERON:0000998	92.07	gold quality
superior surface of tongue	UBERON:0007371	92.03	gold quality
visceral pleura	UBERON:0002401	91.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.87

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

103 targeting TIPRL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-202-5P	99.78	67.65	991

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 40.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 8)

• Data indicate that PP2A holoenzyme biogenesis and activity are controlled by five PP2A modulators, consisting of alpha4, PTPA, LCMT1, PME-1 and TIPRL1, which serve to prevent promiscuous phosphatase activity until the holoenzyme is completely assembled. (PMID:22443683)
• TIPRL is highly up-regulated in human HCC samples and cell lines, compared with noncancerous liver tissues. (PMID:22841785)
• Unlike yeast TIP41, TIPRL has a positive effect on mTORC1 signaling through the association with PP2Ac. (PMID:23892082)
• overexpression of TIPRL promotes phosphorylation of H2AX, and increases gamma-H2AX positive foci in response to DNA damage, whereas knockdown of TIPRL inhibits gamma-H2AX phosphorylation (PMID:26717153)
• MPC2 rs10489202 was genome-wide significantly associated with schizophrenia. The expression quantitative trait loci analysis in lymphoblastoid cell lines from East Asian donors revealed that MPC2 rs10489202 was specifically and significantly associated with the expression of TIPRL gene. (PMID:30087317)
• The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer. (PMID:31727942)
• TIPRL potentiates survival of lung cancer by inducing autophagy through the eIF2alpha-ATF4 pathway. (PMID:31862913)
• TIPRL, a Potential Double-edge Molecule to be Targeted and Re-targeted Toward Cancer. (PMID:38888871)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tiprl	ENSDARG00000032353
mus_musculus	Tiprl	ENSMUSG00000040843
rattus_norvegicus	Tiprl	ENSRNOG00000003048
drosophila_melanogaster	CG9578	FBGN0031094
caenorhabditis_elegans		WBGENE00022803

Protein

Protein identifiers

TIP41-like protein — O75663 (reviewed: O75663)

Alternative names: Putative MAPK-activating protein PM10, Type 2A-interacting protein

All UniProt accessions (1): O75663

UniProt curated annotations — full annotation on UniProt →

Function. May be a allosteric regulator of serine/threonine-protein phosphatase 2A (PP2A). Isoform 1 inhibits catalytic activity of the PP2A(D) core complex in vitro. The PP2A(C):TIPRL complex does not show phosphatase activity. Acts as a negative regulator of serine/threonine-protein phosphatase 4 probably by inhibiting the formation of the active PPP4C:PPP4R2 complex; the function is proposed to implicate it in DNA damage response by promoting H2AX phosphorylated on Ser-140 (gamma-H2AX). May play a role in the regulation of ATM/ATR signaling pathway controlling DNA replication and repair.

Subunit / interactions. Isoform 1 interacts with PPP2CA. Isoform 2 does not interact with PPP2CA. Interacts with PPP2CB, PPP4C and PPP6C. Interacts with IGBP1; the interaction is dependent on PPP2CA. Associates with a protein phosphatase 2A PP2A(C):IGBP1 complex. Interacts with PPP4C and PPP4R2.

Subcellular location. Cytoplasm.

Similarity. Belongs to the TIP41 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O75663-1	1	yes
O75663-2	2, TIP_i2

RefSeq proteins (2): NP_001026970, NP_690866* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007303	TIP41-like	Family
IPR051330	Phosphatase_reg/MetRdx	Family

Pfam: PF04176

UniProt features (33 total): strand 12, helix 8, mutagenesis site 5, modified residue 2, turn 2, splice variant 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5D9G	X-RAY DIFFRACTION	2.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75663-F1	85.04	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 106, 265

Mutagenesis-validated functional residues (5):

Position	Phenotype
198	abolishes interaction with ppp2ca, ppp2cb and ppp4c.
71	abolishes interaction with ppp2ca, ppp2cb and ppp4c.
79	diminishes interaction with ppp2ca.
136	abolishes interaction with ppp2ca, ppp2cb and ppp4c.
196	abolishes interaction with ppp2ca, ppp2cb and ppp4c.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 151 (showing top): ATF_B, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, CREBP1_Q2, SP1_Q2_01, CREB_Q4, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_DNA_DAMAGE_RESPONSE, ATF3_Q6, CREB_Q2_01, ATF4_Q2, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_TOR_SIGNALING

GO Biological Process (2): DNA damage checkpoint signaling (GO:0000077), TOR signaling (GO:0031929)

GO Molecular Function (3): protein phosphatase inhibitor activity (GO:0004864), protein phosphatase activator activity (GO:0072542), protein binding (GO:0005515)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphoprotein phosphatase activity	2
protein phosphatase regulator activity	2
cellular anatomical structure	2
DNA integrity checkpoint signaling	1
signal transduction in response to DNA damage	1
intracellular signal transduction	1
phosphatase inhibitor activity	1
phosphatase activator activity	1
binding	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2216 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TIPRL	PPP4C	P33172	957
TIPRL	PPP2CA	P05323	952
TIPRL	PPP6C	O00743	879
TIPRL	MAP2K7	O14733	821
TIPRL	LCMT1	Q9UIC8	710
TIPRL	IGBP1	P78318	670
TIPRL	PPP2R1A	P30153	595
TIPRL	TBCEL	Q5QJ74	570
TIPRL	TUB	P50607	547
TIPRL	PLCH1	Q4KWH8	517
TIPRL	PTPA	Q15257	516
TIPRL	ATM	Q13315	495
TIPRL	PPME1	Q9Y570	470
TIPRL	EEF1A2	P54266	467
TIPRL	EEF1A1	P04719	434

IntAct

70 interactions, top by confidence:

A	B	Type	Score
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R1A	STRN	psi-mi:“MI:2364”(proximity)	0.880
PPP6C	ANKRD28	psi-mi:“MI:0914”(association)	0.870
TIPRL	PPP4C	psi-mi:“MI:0914”(association)	0.850
PPP4C	TIPRL	psi-mi:“MI:0407”(direct interaction)	0.850
PPP4C	TIPRL	psi-mi:“MI:0915”(physical association)	0.850
PPP4R2	TIPRL	psi-mi:“MI:0914”(association)	0.800
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PPP6C	TIPRL	psi-mi:“MI:0407”(direct interaction)	0.700
TIPRL	PPP6C	psi-mi:“MI:0915”(physical association)	0.700
DYNLT1	DYNC1LI2	psi-mi:“MI:0914”(association)	0.640
PPP4C	SUPT5H	psi-mi:“MI:0914”(association)	0.640
PPP2CB	TIPRL	psi-mi:“MI:0407”(direct interaction)	0.590
TIPRL	PPP2CA	psi-mi:“MI:0915”(physical association)	0.590
PPP4R2	SF3B1	psi-mi:“MI:0914”(association)	0.570
PPP4R2	SF3B1	psi-mi:“MI:2364”(proximity)	0.570
L3MBTL1	DNAJB6	psi-mi:“MI:0914”(association)	0.530
PPP2R1A	ENSA	psi-mi:“MI:0914”(association)	0.530
DYNLT2B	TIPRL	psi-mi:“MI:0914”(association)	0.510
PPP2CA	TIPRL	psi-mi:“MI:0914”(association)	0.500
PPP2CA	TIPRL	psi-mi:“MI:0915”(physical association)	0.500

BioGRID (157): TIPRL (Affinity Capture-MS), TIPRL (Affinity Capture-Western), TIPRL (Affinity Capture-Western), IGBP1 (Affinity Capture-Western), Ppp2ca (Affinity Capture-Western), ARHGAP44 (Co-fractionation), MCMBP (Co-fractionation), NPEPL1 (Co-fractionation), SH3BP1 (Co-fractionation), TIPRL (Co-fractionation), TIPRL (Co-fractionation), TIPRL (Co-fractionation), TIPRL (Co-fractionation), TIPRL (Co-fractionation), TIPRL (Co-fractionation)

ESM2 similar proteins: A1BDQ9, A1DPK7, A8G2V3, B3EFT2, B3EM52, B4S4Y9, B4SCX8, B6YS15, C0SPB1, C4QGM3, C7ZPG2, O15145, O32042, O41126, O48397, O75663, O92551, P04028, P05673, P06942, P06944, P09877, P0C141, P0C571, P0CA30, P0CA85, P0CA86, P13137, P13844, P18611, P20402, P24730, P35976, P41358, Q01639, Q1ECJ7, Q1WTX9, Q32RZ2, Q3T035, Q54EY1

Diamond homologs: A2VCX1, O75663, P34274, Q12199, Q54MI6, Q5FW12, Q6IRA8, Q8BH58, Q8VXY4, Q9USK5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1208 predictions. Top by Δscore:

Variant	Effect	Δscore
1:168179161:G:GT	donor_gain	1.0000
1:168179171:G:GT	donor_gain	1.0000
1:168179175:TGGAG:T	donor_gain	1.0000
1:168179179:G:GT	donor_gain	1.0000
1:168179179:GAA:G	donor_gain	1.0000
1:168179182:G:GG	donor_gain	1.0000
1:168183935:T:TA	acceptor_gain	1.0000
1:168183940:T:TA	acceptor_gain	1.0000
1:168184768:T:TA	acceptor_gain	1.0000
1:168191367:A:AG	acceptor_gain	1.0000
1:168191367:AG:A	acceptor_gain	1.0000
1:168191367:AGGTT:A	acceptor_gain	1.0000
1:168191368:G:GT	acceptor_gain	1.0000
1:168191368:GG:G	acceptor_gain	1.0000
1:168191368:GGT:G	acceptor_gain	1.0000
1:168191368:GGTT:G	acceptor_gain	1.0000
1:168191368:GGTTG:G	acceptor_gain	1.0000
1:168191496:AGATT:A	donor_gain	1.0000
1:168191497:GATT:G	donor_gain	1.0000
1:168191497:GATTG:G	donor_gain	1.0000
1:168191498:ATTG:A	donor_loss	1.0000
1:168191499:TT:T	donor_gain	1.0000
1:168191500:TGTG:T	donor_loss	1.0000
1:168191501:G:GG	donor_gain	1.0000
1:168191501:G:T	donor_loss	1.0000
1:168191504:A:AG	donor_gain	1.0000
1:168191505:G:GG	donor_gain	1.0000
1:168196542:TCCA:T	acceptor_loss	1.0000
1:168196544:CAGAG:C	acceptor_gain	1.0000
1:168196545:A:AG	acceptor_gain	1.0000

AlphaMissense

1816 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:168183945:T:C	F50L	1.000
1:168183947:T:A	F50L	1.000
1:168183947:T:G	F50L	1.000
1:168184068:T:A	W91R	1.000
1:168184068:T:C	W91R	1.000
1:168184070:G:C	W91C	1.000
1:168184070:G:T	W91C	1.000
1:168184822:T:A	W110R	1.000
1:168184822:T:C	W110R	1.000
1:168184824:G:C	W110C	1.000
1:168184824:G:T	W110C	1.000
1:168184846:G:A	G118R	1.000
1:168184846:G:C	G118R	1.000
1:168191463:T:C	L160P	1.000
1:168191469:A:C	D162A	1.000
1:168191469:A:T	D162V	1.000
1:168191475:G:A	G164E	1.000
1:168179129:T:A	W18R	0.999
1:168179129:T:C	W18R	0.999
1:168183934:C:A	P46H	0.999
1:168183940:T:C	M48T	0.999
1:168183940:T:G	M48R	0.999
1:168183945:T:A	F50I	0.999
1:168183956:C:A	N53K	0.999
1:168183956:C:G	N53K	0.999
1:168183997:T:C	F67S	0.999
1:168184012:C:A	A72E	0.999
1:168184847:G:A	G118E	0.999
1:168191406:T:C	L141S	0.999
1:168191456:G:C	D158H	0.999

dbSNP variants (sampled 300 via entrez): RS1000113715 (1:168182243 G>A,C), RS1000187322 (1:168194958 A>G), RS1000301209 (1:168189102 C>G), RS1000306552 (1:168178292 ATT>A,AT,ATTT), RS1000467935 (1:168182010 G>A,T), RS1000635112 (1:168187829 G>A), RS1000831370 (1:168194599 A>G), RS1000924313 (1:168193445 T>C), RS1000963310 (1:168182884 C>A,T), RS1001075815 (1:168196442 T>C), RS1001269762 (1:168182601 G>A), RS1001431072 (1:168196348 T>A,C), RS1001442334 (1:168197108 G>A), RS1001524197 (1:168177901 A>T), RS1001661404 (1:168178194 C>A,T)

Disease associations

OMIM: gene MIM:611807 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST011741_65	LDL cholesterol levels in HIV infection	8.000000e-06
GCST90002404_436	Red cell distribution width	6.000000e-21

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067004 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 2 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.16	Kd	7005	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149592: Binding affinity to human TIPRL incubated for 45 mins by Kinobead based pull down assay	kd	7.0055	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases methylation, decreases expression, increases expression	5
sodium arsenite	affects binding, increases reaction, affects cotreatment, increases abundance, increases expression	2
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
testosterone enanthate	affects expression	1
sodium arsenate	increases expression	1
decabromobiphenyl ether	decreases expression	1
arsenite	affects binding, increases reaction	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
LDN 193189	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
MT19c compound	increases expression	1
bisphenol AF	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	affects expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cisplatin	decreases response to substance, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652634	Binding	Binding affinity to human TIPRL incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3JA	Abcam HEK293T TIPRL KO	Transformed cell line	Female
CVCL_TS42	HAP1 TIPRL (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.